SCHEMBL7879689

SCHEMBL7879689

CNC(N)=NC(=O)c1cc2ccc(OCCN3CCCC3)cc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.59
PDGFRB P09619 3/20 0.53
PDGFRA P16234 2/20 0.53
DRD3 P35462 13/20 0.52
DRD2 P14416 9/20 0.52
LTA4H P09960 1/20 0.45
ADRB1 P08588 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2C P18825 1/20 0.45
HTR2B P41595 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879718 0.95 FLT3 (0.54) FLT3PDGFRBPDGFRADRD3DRD2
SCHEMBL7879728 0.85 FLT3 (0.43) FLT3PDGFRBPDGFRADRD3DRD2
SCHEMBL7882051 0.85 FLT3 (0.48) FLT3PDGFRBPDGFRADRD3DRD2
Hydrochloric Acid SCHEMBL7881414 0.84 FLT3 (0.42) FLT3PDGFRBPDGFRADRD3DRD2
Hydrochloric Acid SCHEMBL7877871 0.83 DRD3 (0.43) FLT3PDGFRBPDGFRADRD3DRD2
SCHEMBL7877830 0.83 DRD3 (0.46) FLT3PDGFRBPDGFRADRD3DRD2
SCHEMBL7880874 0.83 RXFP1 (0.42) FLT3
Hydrochloric Acid SCHEMBL8628104 0.83 FLT3 (0.41) FLT3PDGFRBPDGFRADRD3DRD2
Hydrochloric Acid SCHEMBL7879744 0.83 FLT3 (0.41) FLT3PDGFRBPDGFRADRD3DRD2
SCHEMBL7884296 0.82 KDR (0.40) FLT3PDGFRBPDGFRADRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed